icone plus
Contact Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité DUPIXENT (dupilumab).
Voir aussi
Décision d'accès précoce
14/11/2024
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
8VEJhqBCVkuUycXx
Écouter
